Upsized offering delivers $100M payoff to argenx as another biotech joins the IPO parade
The Dutch antibody shop argenx is the latest biotech to join the growing IPO parade on Nasdaq.
The biotech raised $100 million on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
